Newsroom

Sorted by: Latest

-

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and a...
-

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri...
-

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026...
-

NVIDIA Nemotron Powers Ceramic Supervised Generation to Ground AI Responses at Enterprise Scale

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ceramic, an AI-native search infrastructure company, today unveiled Supervised Generation at NVIDIA GTC 2026 — a system that augments large language model (LLM) outputs with real-time verification, citations and confidence signals. Supervised Generation is model-agnostic, operating as a trust layer alongside any existing LLM infrastructure, with NVIDIA Nemotron 3 Nano as the featured verification engine. To sign up for our waitlist, visit ceramic.ai, or vis...
-

Beazer Homes Announces Expansion of Revolving Credit Facility to $525 million

ATLANTA--(BUSINESS WIRE)--Beazer Homes USA, Inc. (the “Company”) (NYSE: BZH) announced that it has entered into a third amendment to its existing senior unsecured revolving credit facility (“Credit Facility”) that increased the available aggregate commitment amount by $160 million to $525 million. The amendment also extends the maturity date of the Credit Facility from March 15, 2028 to March 13, 2030. The amendment to the Credit Facility was arranged by JP Morgan Chase Bank, N.A., Royal Bank o...
-

SingleCell Biotechnology to Present High-Throughput Single-Cell Phenotyping Platform at AACR Annual Meeting

DALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, today announced that data from its platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, to be held in San Diego, April 17-21, 2026. Relapse remains one of the most persistent challenges in oncology. While many therapies successfully reduce tumor size, a subset of tumor cells can survive trea...
-

NuORDER by Lightspeed anuncia una colaboración con Boozt para fomentar las compras basadas en datos con el fin de estimular el crecimiento

MONTREAL--(BUSINESS WIRE)--NuORDER by Lightspeed anuncia una nueva colaboración estratégica con Boozt, un minorista digital líder en los países nórdicos, con el fin de integrar más inteligencia de compra en sus operaciones y favorecer el crecimiento continuo de NuORDER en los mercados europeos. Esta colaboración sustituye las hojas de cálculo dispersas y los flujos de trabajo manuales por una plataforma centralizada que conecta la variedad de productos, los pedidos y los datos de los productos,...
-

Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026...
-

Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001 at AACR 2026...
-

Oklo’s Atomic Alchemy Announces U.S. Department of Energy Approval for Nuclear Safety Design Agreement of its Groves Isotopes Test Reactor

LOCKHART, Texas--(BUSINESS WIRE)--Oklo Inc. (NYSE: OKLO) (“Oklo”), an advanced nuclear technology company, today announced the U.S. Department of Energy (DOE) has approved the Nuclear Safety Design Agreement (NSDA) for Atomic Alchemy’s Groves Isotopes Test Reactor in Texas under the DOE’s Reactor Pilot Program (RPP). The NSDA approval for Oklo’s wholly owned subsidiary follows the announcement of the signing of the Other Transaction Agreement (OTA) for the facility in January and is a major mil...